Tau NexGen Trial Now Also Testing Anti-Amyloid Therapy Lecanemab

Tau NexGen Trial Now Also Testing Anti-Amyloid Therapy Lecanemab

313199

Tau NexGen Trial Now Also Testing Anti-Amyloid Therapy Lecanemab

The Tau Next Generation (Tau NexGen) clinical trial will now be evaluating an anti-amyloid antibody in addition to an anti-tau antibody as a potential treatment for early onset Alzheimer’s disease, according to a press release. BioArctic and Eisai‘s investigational treatment lecanemab has been selected as the background anti-amyloid agent to be used for the first arm of the trial, the researchers announced. Lecanemab was chosen by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), the network of…

You must be logged in to read/download the full post.